Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved a new oral tyrosine kinase inhibitor with potent, reversible, selective dual inhibition of epidermal growth factor receptor (EGFR) and ErbB2 kinases.

Lapatinib Tablets (Tykerb®)